Want to see DE:HNL full AI Analyst Report?
HNL Stock Chart & Stats
€7.96
-€0.10(-1.26%)
At close: 4:00 PM EDT
€7.96
-€0.10(-1.26%)
Day’s Range― - ―
52-Week Range€6.48 - €10.40
Previous CloseN/A
Volume1.49K
Average Volume (3M)6.13K
Market Cap
€47.65M
Enterprise Value€91.45
Total Cash (Recent Filing)€7.04M
Total Debt (Recent Filing)€48.01M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.13
Revenue Forecast (FY)€94.50M
Bulls Say, Bears Say
Bulls Say
Recurring Aftermarket RevenueHönle's installed base and consumables/spare-parts model creates durable, repeatable revenue and service touchpoints. Aftermarket sales and service support margin stability, predictable cash flows, and cross-sell opportunities (measurement, adhesives) that cushion equipment cyclicality.
Improving Cash GenerationThe company shifted from earlier negative free cash flow to sustained positive operating and free cash flow, improving liquidity and funding ability. This strengthens operational resilience, supports reinvestment in product development and LED transitions, and reduces short-term refinancing pressure.
Manageable LeverageModerate, stable leverage (D/E ~0.63) and meaningful equity provide financial flexibility compared with highly leveraged peers. This balance-sheet headroom supports continued investment in technology and selective capex without immediate distress, aiding long-term strategic execution.
Bears Say
Multi-year Revenue DeclineSustained top-line contraction reduces economies of scale and pressures gross and operating margins over time. Continuous revenue declines complicate long-term planning, limit ability to absorb fixed costs, and make it harder to fund R&D or expand recurring aftermarket sales at scale.
Negative Returns On EquityA negative ROE indicates the firm is destroying shareholder capital rather than generating returns, limiting its ability to attract new equity and reducing internal funding for growth. Persistent negative ROE raises the bar for operational turnaround to restore investor confidence.
Limited Deleveraging CapacityAlthough cash generation is positive, operating cash covers a small share of outstanding debt, constraining meaningful deleveraging without material profit improvement or external financing. This limits scope for large M&A, faster rollout of new tech, or aggressive capex.
Dr. Hoenle AG News
HNL FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest stock price was €6.48 and its highest was €10.40 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €47.65M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is Aug 18, 2026 which is in 20 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on May 19, 2026. The company reported €0.11 earnings per share for the quarter, the consensus estimate of €0.11 by €0.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of €0.11 in its last earnings report, expectations of €0.11. Following the earnings report the stock price went up 0.846%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in DE:HNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.37%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG is a global provider specializing in industrial ultraviolet (UV) technologies and related systems, with operations spanning Germany and international markets. The company organizes its business into three main segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives division develops industrial bonding solutions for critical applications within sectors such as consumer electronics, medical technology, optics and opto-electronics, the automotive industry, and glass processing. Its Equipment & Systems segment focuses on developing solutions for the efficient drying of inks and coatings, the precise curing of adhesives and plastics, comprehensive surface disinfection, and advanced solar simulation. Lastly, the Glass & Lamps division manufactures quartz glass tubing and rods, which are vital for the lamp, automotive, semiconductor, and fiber optic cable industries, alongside producing specialized lamps utilized for water purification and the drying of various coatings and adhesives. Founded in 1976, Dr. Hönle AG is headquartered in Munich, Germany.
Technical Analysis
LPKF Laser & Electronics
―
Manz AG
―
MAX Automation
―
Singulus Technologies
―
Suss Microtec
―